Objectives: To assess the value of urine tumor-associated trypsin inhibitor (TATI), CYFRA 21-1, which measures cytokeratin 19 fragment, and urinary bladder carcinoma antigen (UBC) for the detection of high-grade bladder carcinoma.
Methods: A total of 160 individuals were enrolled in the present study. Of these, 80 were patients with proven primary high-grade urothelial bladder cancer (group 1), 40 were healthy volunteers (group 2), and 40 had history of benign urologic disease (group 3). All were evaluated with respect to urinary TATI, CYFRA 21-1, and UBC levels. All these markers were evaluated using commercial kits. Cytology was also performed.
Results: The TATI measurements were significant greater in group 1 compared with groups 2 and 3. The cutoff point used for TATI, CYFRA 21-1, and UBC was 22, 2.8, and 12 microg/L, respectively. The overall sensitivity was 85.7% for TATI, 61.9% for CYFRA 21-1, 50% for UBC, and 42.8% for cytology. TATI was significantly more sensitive in Stage Ta (80%) than was CYFRA 21-1 (32%), UBC (12%), and cytology (20%). TATI was also more sensitive compared with other tumor markers for Stage T1 but not for Stage T2 or T3.
Conclusions: The results of our study have shown that TATI is a promising urinary tumor marker for high-grade urothelial bladder cancer. It is more sensitive than CYFRA 21-1, UBC, and cytology for Stage Ta and T1 bladder cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2008.04.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors for Non-Small Cell Lung Cancer Diagnosis.
Sensors (Basel)
December 2024
Central Hospital of Dalian University of Technology, Dalian 116021, China.
Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer and poses a significant public health challenge. Early detection is crucial for improving patient outcomes, with serum biomarkers such as carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCAg), and cytokeratin fragment 19 (CYFRA 21-1) playing a critical role in early screening and pathological classification of NSCLC. However, due to being mainly based on corresponding antibody binding reactions, existing detection technologies for these serum biomarkers have shortcomings such as complex operations, high false positive rates, and high costs.
View Article and Find Full Text PDFEnhanced Analytical Performance in CYFRA 21-1 Detection Using Lateral Flow Assay with Magnetic Bioconjugates: Integration and Comparison of Magnetic and Optical Registration.
Biosensors (Basel)
December 2024
Prokhorov General Physics Institute of the Russian Academy of Sciences, 38 Vavilov Street, 119991 Moscow, Russia.
A novel approach to developing lateral flow assays (LFAs) for the detection of CYFRA 21-1 (cytokeratin 19 fragment, a molecular biomarker for epithelial-origin cancers) is proposed. Magnetic bioconjugates (MBCs) were employed in combination with advanced optical and magnetic tools to optimize assay conditions. The approach integrates such techniques as label-free spectral-phase interferometry, colorimetric detection, and ultrasensitive magnetometry using the magnetic particle quantification (MPQ) technique.
View Article and Find Full Text PDFAssessing the 9G Technology Blood Test for Predicting Lung Cancer in Patients with CT-Detected Lung Nodules: A Multicenter Clinical Trial.
Cancers (Basel)
November 2024
Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul 05029, Republic of Korea.
: Lung nodules detected by chest computed tomography (CT) often require invasive biopsies for definitive diagnosis, leading to unnecessary procedures for benign lesions. A blood-based biomarker test that predicts lung cancer risk in CT-detected nodules could help stratify patients and direct invasive diagnostics toward high-risk individuals. : In this multicenter, single-blinded clinical trial, we evaluated a test measuring plasma levels of p53, anti-p53 autoantibodies, CYFRA 21-1, and anti-CYFRA 21-1 autoantibodies in patients with CT-detected lung nodules.
View Article and Find Full Text PDFDetection of Protein Markers From Blood Samples of Cervical Cancer Patients.
Cureus
October 2024
Microbiology, University of Dhaka, Dhaka, BGD.
Article Synopsis
- The study investigates the role of serum proteins as biomarkers for early detection of HPV-related cervical cancer, focusing on proteins like CEA, SCCA, HMGB1, and CYFRA 21-1.
- Analysis of blood samples from 36 cervical cancer patients revealed that CEA was the most frequently detected protein, highlighting variations based on different HPV types.
- The findings suggest that CEA could serve as a reliable biomarker for cervical cancer, especially in cases linked to HPV-16, which showed the highest response rates among the tested proteins.
Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer.
Clin Chim Acta
January 2025
Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address:
Article Synopsis
- The study investigated the potential of the abnormal glycan structure Siaα-2,6Gal for diagnosing lung cancer early and differentiating it from other conditions.
- Clinical data and serum samples were analyzed from 730 lung cancer patients and 120 healthy individuals, measuring various serum markers including Siaα-2,6Gal and traditional tumor markers.
- Results showed that Siaα-2,6Gal levels were significantly higher in lung cancer patients, especially in early-stage cases, indicating it may serve as a more effective biomarker than traditional tests for diagnosing lung cancer.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!